By Mill Chart
Last update: Mar 28, 2025
Peter Lynch’s approach focused on identifying undervalued growth stocks with simple, scalable businesses. We examine whether GENMAB A/S -SP ADR (NASDAQ:GMAB) fits the characteristics of a Lynch-approved investment.
As part of its analysis, ChartMill provides a comprehensive Fundamental Rating for each stock. This rating, ranging from 0 to 10, is updated on a daily basis and is based on the evaluation of various fundamental indicators and properties.
We assign a fundamental rating of 7 out of 10 to GMAB. GMAB was compared to 569 industry peers in the Biotechnology industry. GMAB has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. GMAB is evaluated to be cheap and growing strongly. This does not happen too often! This makes GMAB very considerable for value and growth and quality investing!
Our latest full fundamental report of GMAB contains the most current fundamental analsysis.
More Affordable Growth stocks can be found in our Peter Lynch screener.
This article should in no way be interpreted as advice. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
20.04
+0.49 (+2.51%)
Find more stocks in the Stock Screener
GENMAB A/S -SP ADR was identified as a growth stock that isn't overvalued. NASDAQ:GMAB is excelling in various growth indicators while maintaining a solid financial footing.